Full-length antibodies provide Fc-mediated biology and familiar manufacturing routes, but they are not always the optimal molecular architecture. Removing or reconfiguring the Fc region can reduce molecular size, improve access to sterically restricted epitopes, eliminate unwanted Fc effector activity, enable modular fusion, or support multivalent and multispecific designs. Those benefits must be balanced against changes in half-life, avidity, expression, solubility, aggregation, and purification behavior.
Creative Biolabs develops antibody fragments for canine, feline, and other veterinary discovery programs with an integrated design-build-test strategy. We examine the parental sequences, target biology, intended route and duration of exposure, required valency, and downstream assay needs before selecting a format. Each construct is evaluated as a complete molecule rather than as a sequence alone, helping project teams identify a fragment that retains target recognition while meeting practical developability and production requirements.
Service modules can be combined into a single comparison campaign and adapted to available sequence information, material, and project maturity.
Generate monovalent or bivalent antigen-binding fragments through recombinant design or controlled cleavage strategies. Construct boundaries, hinge elements, chain pairing, purification tags, and disulfide behavior are planned to preserve binding and support reproducible production.
Compare VH-linker-VL and VL-linker-VH orientations, linker length and composition, signal peptides, and optional stabilization changes. Expression, monomer content, thermal behavior, and antigen binding are considered together when ranking designs.
Where appropriate, develop compact single-domain binders using suitable scaffolds such as camelid-derived VHH, engineered conventional VH domains, or other validated sdAb formats. Conventional canine or feline VH domains are not assumed to function as standalone binders; exposed VH/VL interface liabilities, solubility, aggregation, affinity retention, and expression behavior are evaluated during design and screening.
Assemble tandem scFvs, diabody-like formats, dual-target constructs, or other multivalent architectures. Domain order, linker geometry, chain pairing, avidity, and unwanted self-association are evaluated against the desired mechanism.
Fc or albumin-binding strategies may be incorporated to extend systemic exposure, while enzymes, cytokines, payloads, or other partners can be introduced to add complementary biological functions. Junctions and linkers are engineered to preserve access and activity across the resulting fusion format.
Assess identity, purity, oligomeric state, aggregation, stability, yield, target binding, kinetics, and fit-for-purpose cell activity. Comparative data distinguish a potent but fragile molecule from a format suitable for continued development.
Our workflow uses connected engineering gates so that format, expression, biophysical quality, and biological function can be iteratively optimized as new data emerge.
Define target biology, species, intended application, valency, Fc requirement, dosing assumptions, controls, and candidate-ranking criteria.
Design boundaries, orientation, linkers, tags, fusion partners, and species-relevant sequence or constant-region elements where applicable, supported by sequence analysis.
Express selected constructs in a suitable host, establish purification conditions, and confirm identity, purity, recovery, and homogeneity.
Measure binding, kinetics, stability, aggregation, oligomeric state, and project-specific cell or biochemical activity.
Refine linkers, orientation, valency, species adaptation, fusion design, or expression conditions using comparative evidence.
Deliver sequences, construct records, production and assay data, candidate ranking, and options for scale-up or downstream evaluation.
| Gate | Activity | Evidence Generated | Decision |
|---|---|---|---|
| Project Assessment & Design Strategy | Translate the veterinary mechanism and product concept into molecular-format, valency, species, expression, and assay requirements. | Design brief, risk register, and comparison plan. | Which fragment architectures should be built? |
| Antibody Fragment Construction | Create sequence-verified Fab, F(ab')2, scFv, multivalent, fusion, and, where appropriate, single-domain constructs with suitable controls and scaffold-specific design criteria. | Expression-ready plasmids and construct map. | Do the designs represent the intended comparison? |
| Expression & Purification | Screen host and purification conditions, then assess yield, identity, purity, and size distribution. | Qualified fragment samples and analytical QC. | Which constructs provide usable, homogeneous material? |
| Biophysical & Functional Characterization | Compare stability and aggregation with antigen binding, kinetics, avidity, and relevant functional readouts. | Cross-assay performance matrix. | Does molecular performance support the mechanism? |
| Format Optimization & Multispecies Adaptation | Iterate orientation, linkers, valency, fusion junctions, species-aware sequence choices, constant-region elements where applicable, or production parameters. | Optimized variants and confirmatory data. | Which changes improve the overall profile? |
| Comprehensive Reporting & Next-Step Integration | Consolidate methods and data and define scale-up, conjugation, formulation, characterization, or in vivo study options. | Final report, sequences, data files, and material. | What is required to advance the selected fragment? |
Share the parental antibody sequence, target, species, and intended function; we can propose a practical comparison set.
Pirkalkhoran et al. summarized the opportunities and constraints of bacterial, mammalian, plant, and baculovirus-insect expression platforms for Fab and scFv production. The comparison shows why fragment development cannot treat expression as a downstream commodity: molecular complexity, folding, post-translational processing, endotoxin control, yield, purification burden, and cost can alter both the practical route and the quality of material available for testing.
This evidence supports an integrated engineering approach in which fragment architecture and production platform are selected together. Creative Biolabs can screen construct orientation, linker design, secretion strategy, expression host, and purification conditions before comparing antigen binding, stability, oligomeric state, and functional activity. For veterinary programs, that coordinated workflow helps avoid advancing a sequence that performs in an isolated binding assay but cannot be produced as a stable, homogeneous development candidate.
Our service connects molecular architecture to manufacturability and biological function, with the flexibility to support a single construct or a comparative format campaign.
